

Controlled substance	Drug code	Schedule
Desomorphine .....	9055	I
Dihydromorphine .....	9145	I
Heroin .....	9200	I
Morphine-N-oxide .....	9307	I
Normorphine .....	9313	I
Tilidine .....	9750	I
Alpha-methylfentanyl .....	9814	I
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) .....	9821	I
Methamphetamine .....	1105	II
Phenmetrazine .....	1631	II
Methylphenidate .....	1724	II
Amobarbital .....	2125	II
Pentobarbital .....	2270	II
Secobarbital .....	2315	II
Glutethimide .....	2550	II
Phencyclidine .....	7471	II
Phenylacetone .....	8501	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Ethylmorphine .....	9190	II
Hydrocodone .....	9193	II
Levorphanol .....	9220	II
Meperidine .....	9230	II
Meperidine intermediate-B .....	9233	II
Meperidine intermediate-C .....	9234	II
Dextropropoxyphene, bulk (non-dosage forms) .....	9273	II
14-Hydroxymorphine .....	9665	II
Noroxymorphone .....	9668	II
Sufentanil .....	9740	II
Fentanyl .....	9801	II

The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols) the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinols. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-08328 Filed 4-17-20; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-621]

#### **Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Groff NA Hemplex LLC**

**ACTION:** Notice of application.

**SUMMARY:** The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other

pending applications according to proposed regulations that, if finalized, would govern the program of growing marihuana for scientific and medical research under DEA registration.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections to the issuance of the proposed registration on or before June 19, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW 8701 Morrisette Drive, Springfield, Virginia 22152. To ensure proper handling of comments, please reference Docket No. DEA-621 in all correspondence, including attachments.

**SUPPLEMENTARY INFORMATION:** The Controlled Substances Act (CSA) prohibits the cultivation and distribution of marihuana except by persons who are registered under the CSA to do so for lawful purposes. In accordance with the purposes specified in 21 CFR 1301.33(a), DEA is providing notice that the entity identified below has applied for registration as a bulk manufacturer of schedule I controlled substances. In response, registered bulk manufacturers of the affected basic class(es), and applicants therefor, may file written comments on or objections

of the requested registration, as provided in this notice. This notice does not constitute any evaluation or determination of the merits of the application submitted.

The applicant plans to manufacture bulk active pharmaceutical ingredients (APIs) for product development and distribution to DEA-registered researchers. If the application for registration is granted, the registrant would not be authorized to conduct other activity under this registration aside from those coincident activities specifically authorized by DEA regulations. DEA will evaluate the application for registration as a bulk manufacturer for compliance with all applicable laws, treaties, and regulations and to ensure adequate safeguards against diversion are in place.

As this applicant has applied to become registered as a bulk manufacturer of marihuana, the application will be evaluated under the criteria of 21 U.S.C. 823(a). DEA proposes to conduct this evaluation in the manner described in the rule proposed at 85 FR 16292, published on March 23, 2020, if finalized.

In accordance with 21 CFR 1301.33(a), DEA is providing notice that on February 28, 2020, Groff NA Hemplex LLC, 100 Redco Avenue, Suite

A, Red Lion, Pennsylvania 17356–1436, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
marihuana .....	7360	I
tetrahydrocannabinols .....	7370	I

The applicant’s notice above applied to become registered with DEA to grow marihuana as a bulk manufacturer subsequent to a 2016 DEA policy statement that provided information on how it intended to expand the number of registrations, and described in general terms the way it would oversee those additional growers. In order to complete the evaluation and registration process for applicants to grow marihuana, DEA has proposed regulations that, if finalized, would supersede the 2016 policy statement and govern persons seeking to become registered with DEA to grow marihuana as a bulk manufacturer, consistent with applicable law. The proposed regulations are available at 85 FR 16292.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. 2020–08334 Filed 4–17–20; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–622]

**Bulk Manufacturer of Controlled Substances Application: AMRI Rensselaer, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 19, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 9, 2020, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144–2951, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Amphetamine .....	1100	II
Lisdexamfetamine .....	1205	II
Pentobarbital .....	2270	II
ANPP (4-Anilino-N-phenethyl-4-piperidine).	8333	II
Codeine .....	9050	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Hydrocodone .....	9193	II
Meperidine .....	9230	II
Morphine .....	9300	II
Fentanyl .....	9801	II

The company plans to manufacture the above controlled substances as bulk active pharmaceutical ingredients (APIs) for use in product development and for distribution to its customers. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. 2020–08330 Filed 4–17–20; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–609]

**Importer of Controlled Substances Application: Purisys, LLC**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 20, 2020. Such persons may also file a written request for a hearing on the application on or before May 20, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration,

Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on January 30, 2020, Purisys, LLC, 1550 Olympic Drive, Athens, Georgia 30601–1602 applied to be registered as an importer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana Extract .....	7350	I
Marihuana .....	7360	I
Tetrahydrocannabinols ...	7370	I
Nabilone .....	7379	II
Phenylacetone .....	8501	II
Levorphanol .....	9220	II
Thebaine .....	9333	II
Poppy Straw Con- centrate.	9670	II
Tapentadol .....	9780	II

The company plans to import drug code 8501, Phenylacetone and drug code 9670, Poppy Straw Concentrate to bulk manufacture other controlled substances for distribution to its customers. The company plans to import impurities of buprenorphine that have been determined by DEA to be captured under drug code 9333, Thebaine. In reference to drug codes 7360, Marihuana and 7370, Tetrahydrocannabinols the company plans to import a Synthetic Cannabidiol and a Synthetic Tetrahydrocannabinol. No other activity for these drug codes is authorized for this registration. Placement of these drug codes on the company’s registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. 2020–08270 Filed 4–17–20; 8:45 am]

**BILLING CODE 4410–09–P**